Structural Basis of PER-1-Mediated Cefiderocol Resistance and Synergistic Inhibition of PER-1 by Cefiderocol in Combination with Avibactam or Durlobactam in Acinetobacter baumannii

Cefiderocol is a novel siderophore cephalosporin that displays activity against Gram-negative bacteria. To establish cefiderocol susceptibility levels of Acinetobacter baumannii strains from China, we performed susceptibility testing and genomic analyses on 131 clinical isolates. ABSTRACT Cefiderocol is a novel siderophore cephalosporin that displays activity against Gram-negative bacteria. To establish cefiderocol susceptibility levels of Acinetobacter baumannii strains from China, we performed susceptibility testing and genomic analyses on 131 clinical isolates. Cefiderocol shows high activity against the strains. The production of PER-1 is the key mechanism of cefiderocol resistance. In silico studies predicted that avibactam and durlobactam could inhibit cefiderocol hydrolysis by PER-1, which was confirmed by determining cefiderocol MICs in combination with inhibitors.

[1]  W. van Schaik,et al.  Alcaligenes faecalis metallo-β-lactamase in extensively drug-resistant Pseudomonas aeruginosa isolates. , 2021, Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases.

[2]  M. Holubar,et al.  Cefiderocol: A new cephalosporin stratagem against multidrug resistant gram-negative bacteria. , 2021, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[3]  S. McLeod,et al.  Durlobactam, a New Diazabicyclooctane β-Lactamase Inhibitor for the Treatment of Acinetobacter Infections in Combination With Sulbactam , 2021, Frontiers in Microbiology.

[4]  P. Nordmann,et al.  Contribution of PER-Type and NDM-Type β-Lactamases to Cefiderocol Resistance in Acinetobacter baumannii , 2021, Antimicrobial agents and chemotherapy.

[5]  W. van Schaik,et al.  Acquisition of a genomic resistance island (AbGRI5) from global clone 2 through homologous recombination in a clinical Acinetobacter baumannii isolate. , 2020, The Journal of antimicrobial chemotherapy.

[6]  Jun Wu,et al.  BacAnt: A Combination Annotation Server for Bacterial DNA Sequences to Identify Antibiotic Resistance Genes, Integrons, and Transposable Elements , 2021, Frontiers in microbiology.

[7]  Robin Patel,et al.  Cefiderocol Antimicrobial Susceptibility Testing Considerations: the Achilles' Heel of the Trojan Horse? , 2020, Journal of Clinical Microbiology.

[8]  M. Hackel,et al.  Reduced susceptibility mechanism to cefiderocol, a siderophore cephalosporin, among clinical isolates from global surveillance program (SIDERO-WT-2014). , 2020, Journal of global antimicrobial resistance.

[9]  F. Fernández-Cuenca,et al.  Activity of cefiderocol against high-risk clones of multidrug-resistant Enterobacterales, Acinetobacter baumannii, Pseudomonas aeruginosa and Stenotrophomonas maltophilia , 2020, The Journal of antimicrobial chemotherapy.

[10]  C. Ayoub Moubareck,et al.  Insights into Acinetobacter baumannii: A Review of Microbiological, Virulence, and Resistance Traits in a Threatening Nosocomial Pathogen , 2020, Antibiotics.

[11]  S. Shelburne,et al.  Activity of Cefiderocol and Comparators against Isolates from Cancer Patients , 2020, Antimicrobial Agents and Chemotherapy.

[12]  D. Landman,et al.  Activity of Cefiderocol Against Enterobacterales, Pseudomonas aeruginosa, and Acinetobacter baumannii Endemic to Medical Centers in New York City , 2020, Microbial drug resistance.

[13]  Y. Yamano In Vitro Activity of Cefiderocol Against a Broad Range of Clinically Important Gram-negative Bacteria , 2019, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[14]  S. Leptihn,et al.  Dual Role of gnaA in Antibiotic Resistance and Virulence in Acinetobacter baumannii , 2019, Antimicrobial Agents and Chemotherapy.

[15]  M. Hackel,et al.  In Vitro Activity of Cefiderocol, a Siderophore Cephalosporin, Against Gram-Negative Bacilli Isolated by Clinical Laboratories in North America and Europe in 2015-2016: SIDERO-WT-2015. , 2019, International journal of antimicrobial agents.

[16]  M. Ploy,et al.  The Role of ISCR1-Borne POUT Promoters in the Expression of Antibiotic Resistance Genes , 2018, Front. Microbiol..

[17]  A. Peleg,et al.  OXA-23 Is a Prevalent Mechanism Contributing to Sulbactam Resistance in Diverse Acinetobacter baumannii Clinical Strains , 2018, Antimicrobial Agents and Chemotherapy.

[18]  Qing Yang,et al.  Evolution of Acinetobacter baumannii In Vivo: International Clone II, More Resistance to Ceftazidime, Mutation in ptk , 2017, Front. Microbiol..

[19]  Y. Ni,et al.  Molecular Epidemiology and Genetic Characteristics of Various blaPER Genes in Shanghai, China , 2016, Antimicrobial Agents and Chemotherapy.

[20]  L. Piddock,et al.  A Method for generating marker-less gene deletions in multidrug-resistant Acinetobacter baumannii , 2013, BMC Microbiology.

[21]  S. Kuo,et al.  Contribution of a Plasmid-Borne blaOXA-58 Gene with Its Hybrid Promoter Provided by IS1006 and an ISAba3-Like Element to β-Lactam Resistance in Acinetobacter Genomic Species 13TU , 2010, Antimicrobial Agents and Chemotherapy.

[22]  P. Nordmann,et al.  Common Region CR1 for Expression of Antibiotic Resistance Genes , 2006, Antimicrobial Agents and Chemotherapy.

[23]  P. Bennett,et al.  ISCR Elements: Novel Gene-Capturing Systems of the 21st Century? , 2006, Microbiology and Molecular Biology Reviews.